| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |